Alvogen has signed a definitive agreement with Exeltis, a division of the global pharmaceutical group Insud Pharma, to acquire a targeted portfolio of prescription and over-the-counter drugs in the field of women’s healthcare. The transaction includes 23 brands with marketing rights in Russia, Ukraine and Kazakhstan. Majority of the brands acquired will continue to be manufactured by Insud Pharma from their high-quality facilities in Spain and Turkey.

Hacho Hatchikian, Executive Vice President of Alvogen CEE, commented: “This transaction provides greater scale and diversity across our portfolio and sales channels, while increasing market share in women’s healthcare in key markets. The acquired brands will compliment, as well as significantly strengthen, Alvogen’s existing portfolio in the region.”